Abstract
INTRODUCTION Subjective cognitive complaints often precede declines in objective measures of cognitive performance. Incipient AD neuropathology may be associated with subjective cognitive complaints prior to detectable associations with neuropsychological testing among cognitively normal individuals.
METHODS We examined the independent associations of PET measures of amyloid-β and tau pathology with longitudinal change in subjective complaints and memory among 91 cognitively normal Baltimore Longitudinal Study of Aging participants using linear mixed effects models. Subjective complaints and memory performance were assessed with the Cognitive Failures Questionnaire and the California Verbal Learning Test, respectively.
RESULTS Greater parahippocampal tau, independent of amyloid, was associated with higher subjective complaints (estimate=0.203, SE=0.0825, p=0.016), while greater entorhinal tau corresponded to an attenuated increase in complaints over time (estimate=-0.0629, SE=0.0299, p=0.040). Hippocampal tau was associated with steeper memory decline (estimate=-0.0279, SE=0.0135, p=0.043).
CONCLUSION Subjective cognitive complaints may serve as early indicators of cerebral tau pathology in cognitively normal individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Intramural Research Program of the National Institute on Aging, NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local institutional review boards (IRB) and the National Institutes of Health, and all participants gave written informed consent at each visit.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos